US equities |
MU $877.55 ▲+0.00% TSLA $372.22 ▲+0.00% SNDK $1,238.03 ▲+0.00% SPCX $147.49 ▲+0.00% NBIS $158.74 ▲+0.00% NVDA $210.96 ▲+0.00% AAPL $347.73 ▲+0.00% NU $15.16 ▲+0.00%
FinancialContent

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

1.220 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectar Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript ↗
Phase 3 trial underway for iopofosine I 131 in Waldenstrom's macroglobulinemia. 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar (CLRB) Q1 2026 Earnings Transcript ↗
Cellectar (CLRB) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar (CLRB) Q4 2025 Earnings Call Transcript ↗
Cellectar (CLRB) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Expands Global Intellectual Property Estate
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Outlook For Cellectar Biosciences ↗
 
Via Benzinga
News headline image
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally ↗
The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in... 
Via Stocktwits
Topics Supply Chain
News headline image
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >